What Is Ozempic (Semaglutide)? Uses, Side Effects, and the Weight Loss Controversy
Few drugs in recent memory have crossed from medical journals into dinner table conversation the way semaglutide has. Ozempic became a cultural phenomenon. Wegovy waitlists stretched for months. Compounding pharmacies flooded the market with unregulated copies. And underneath all of that noise is a genuinely significant advance in metabolic medicine — one that deserves to be understood clearly.
What Semaglutide Is: A GLP-1 Receptor Agonist
Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the small intestine in response to eating. It was first identified because researchers studying Gila monster saliva in the 1990s noticed the lizard's digestive hormones were remarkably potent at stimulating insulin secretion. This led to the entire GLP-1 drug class.
Semaglutide is a synthetic analog of human GLP-1, engineered to have a much longer half-life than the native hormone (which is degraded within minutes). By binding it to a fatty acid chain that attaches to albumin in the bloodstream, Novo Nordisk achieved a half-life of approximately one week — enabling once-weekly injection or, in the oral form (Rybelsus), once-daily dosing.
How It Works: Three Mechanisms, One Drug
GLP-1 receptor agonists operate through several converging pathways:
- Glucose-dependent insulin stimulation: GLP-1 receptors on pancreatic beta cells signal insulin release — but only when blood glucose is elevated. This glucose-dependency is why semaglutide rarely causes hypoglycemia on its own, unlike sulfonylureas or insulin.
- Glucagon suppression: GLP-1 suppresses glucagon secretion from alpha cells, reducing the liver's glucose output between meals.
- Gastric emptying slowdown: Semaglutide significantly delays gastric emptying — food moves more slowly from the stomach into the small intestine. This blunts post-meal glucose spikes and extends the sensation of fullness.
- Central appetite suppression: GLP-1 receptors in the hypothalamus and brainstem are involved in hunger signaling. Semaglutide acts directly on these circuits, reducing appetite and food-seeking behavior beyond what gastric emptying alone would explain.
Approved Indications: Ozempic vs. Wegovy vs. Rybelsus
| Brand Name | Formulation | FDA Indication | Max Dose |
|---|---|---|---|
| Ozempic | Weekly subcutaneous injection | Type 2 diabetes (glycemic control); CV risk reduction in T2D + established CVD | 2 mg/week |
| Wegovy | Weekly subcutaneous injection | Chronic weight management (obesity BMI ≥30, or ≥27 with weight-related condition); CV risk reduction in obesity + established CVD | 2.4 mg/week |
| Rybelsus | Daily oral tablet | Type 2 diabetes | 14 mg/day |
Using Ozempic for weight loss in people without diabetes is technically off-label — a practice that became extremely common and contributed significantly to national shortages. Wegovy contains a higher maximum dose (2.4 mg vs. 2 mg) and is the formally approved weight management product.
What the Clinical Trials Actually Show
The STEP 1 trial, the pivotal Wegovy obesity study, enrolled 1,961 adults with obesity or overweight and weight-related conditions (but without diabetes). After 68 weeks, the semaglutide group lost an average of 14.9% of body weight versus 2.4% for placebo. That's a roughly 15% loss — a level of efficacy previously only associated with bariatric surgery. The SUSTAIN trials demonstrated meaningful HbA1c reductions in type 2 diabetes alongside weight loss of approximately 4–6 kg at diabetes doses.
The SELECT cardiovascular outcomes trial, published in 2023, enrolled over 17,000 adults with established cardiovascular disease and obesity or overweight but without diabetes. Wegovy reduced the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% compared to placebo — independent of weight loss magnitude. This established semaglutide as a cardiovascular drug, not merely a metabolic one, and led to the expanded FDA indication for CV risk reduction.
Side Effects: What to Expect
Gastrointestinal effects
Nausea is the most common side effect, affecting a substantial portion of patients especially during dose titration. It typically improves after 4–8 weeks as the body adjusts. Vomiting, diarrhea, and constipation are also reported. The slow titration protocol (starting at 0.25 mg weekly and increasing every 4 weeks) exists specifically to reduce GI side effects during the dose escalation period. Eating smaller meals, avoiding high-fat foods, and staying upright after eating all help.
PANCREATITIS: GLP-1 agonists have been associated with acute pancreatitis in clinical reports and trials. The absolute risk is low but not negligible. Symptoms include severe, persistent abdominal pain radiating to the back, often with nausea and vomiting. If you experience these symptoms on semaglutide, stop the medication and seek emergency care. Patients with a history of pancreatitis or heavy alcohol use (a major pancreatitis risk factor) should discuss carefully with their prescriber before starting.
THYROID C-CELL TUMORS: Semaglutide carries a black-box warning for thyroid C-cell tumors, based on findings in rodent studies where GLP-1 receptor agonists caused dose-dependent thyroid tumors at exposures far exceeding clinical doses. Whether this risk translates to humans is unknown — epidemiological studies have not found a clear signal, but surveillance is ongoing. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Gastroparesis and food stuck
Some patients on GLP-1 agonists develop a more severe slowing of gastric emptying that goes beyond the intended effect — clinically resembling gastroparesis. This can cause persistent nausea, vomiting of undigested food, and impaired absorption of oral medications. There have been documented cases of patients aspirating stomach contents under anesthesia because their stomach wasn't empty when expected, prompting anesthesiologists to update pre-surgical fasting guidance for GLP-1 users.
The Shortage and Compounded Semaglutide
The surge in demand for both Ozempic and Wegovy caused extended supply shortages. During periods when FDA-approved semaglutide was unavailable, compounding pharmacies were permitted under FDA enforcement discretion to produce semaglutide products. Those compounded versions were made from semaglutide salts (semaglutide sodium, semaglutide acetate) rather than the base compound used in the approved drugs, and were not evaluated for safety, efficacy, or purity by the FDA. Reports of adverse events linked to compounded semaglutide products — including dosing errors that caused severe hypoglycemia — led the FDA to ultimately wind down that enforcement discretion in 2025.
How Semaglutide Compares to Tirzepatide (Mounjaro, Zepbound)
Tirzepatide (Eli Lilly's Mounjaro for diabetes, Zepbound for obesity) is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Head-to-head data from the SURMOUNT-5 trial showed tirzepatide produced approximately 20% body weight reduction versus around 14% for semaglutide — a meaningful additional benefit. Both are now considered first-line agents for obesity pharmacotherapy in appropriate candidates. The choice between them depends on individual tolerability, access, insurance coverage, and prescriber preference.
Frequently Asked Questions
What is Ozempic and how does it work?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist injected once weekly. It works by mimicking the natural incretin hormone GLP-1 — stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and acting on brain receptors to reduce appetite. It was FDA-approved for type 2 diabetes and cardiovascular risk reduction in people with established heart disease.
What is the difference between Ozempic and Wegovy?
Both Ozempic and Wegovy contain semaglutide, but they are approved for different indications and use different maximum doses. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction, while Wegovy is approved for chronic weight management at a higher maximum dose. They use the same molecule but are not interchangeable from a regulatory or prescribing standpoint.
What are the most common side effects of Ozempic?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach discomfort. These are most pronounced when starting treatment or after dose increases, and typically improve over time. Rare but serious risks include pancreatitis, gallbladder disease, and a possible (though not confirmed in humans) risk of thyroid C-cell tumors based on animal studies.
What happens if you stop taking Ozempic?
Most people regain a significant portion of the weight they lost after discontinuing semaglutide, because the drug's appetite-suppressing effects are not permanent. For type 2 diabetes patients, blood sugar levels typically rise after stopping if no alternative management is in place. Ozempic treats these conditions rather than curing them, meaning ongoing use is generally required to maintain benefits.
Want to look up the full side effect profile for semaglutide or compare it with other medications you take?
Explore Side Effects